CNCristina Niţă

Cristina Niţă

*This is an algorithmically generated author record based on publicly available information.

Cristina Niţă has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Nicolae Hancu

    Iuliu Hatieganu University of Medicine and Pharmacy, Clinical Center of Diabetes, Nutrition, and Metabolic Diseases, Cluj-Napoca, Romania

    4 shared publications
  • Adriana Rusu

    Department of Diabetes, Nutrition, Metabolic Diseases, University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania

    1 shared publication
  • Anca Crăciun

    “Iuliu Haţieganu” University of Medicine and Pharmacy, Cluj-Napoca

    1 shared publication
  • Cornelia Bala

    Department of Diabetes and Nutrition Diseases, Faculty of Medicine, “Iuliu Hațieganu” University of Medicine and Pharmacy, 2–4 Clinicilor Street, 400006 Cluj-Napoca, Romania

    1 shared publication
  • Gabriela Roman

    Department of Diabetes and Nutrition Diseases, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania

    1 shared publication
  • Mihai Porojan

    Department of Internal Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania

    1 shared publication

Latest Publications

  • Open Access

    Prevention Of Coronary Heart Disease And Stroke Complications In Type 2 Diabetes Mellitus: An Observational, Prospective Study

    by Ramona Maria Ştefan, Cristina Niţă, Anca Crăciun, Adriana Rusu, Nicolae Hâncu

    Background and Aims: We assessed the effect of intensive therapy on modifiable cardiovascular (CV) risk factors and CV risk as compared to conventional therapy in patients with newly diagnosed type 2 diabetes mellitus (T2DM).Material and Methods: This was an observational, prospective study, conducted in Romania. During 1-year follow-up period the enrolled participants received either multi-factorial pharmacotherapy associated with intensive therapeutic education (Intensive group), or conventional therapy (Control group). Current analysis included data (anthropometric measurements, blood pressure and biochemical parameters) recorded at months (M) 0, 6 and 12. CV risk was calculated at M1 and M12 using the UK Prospective Diabetes Study Risk Engine.Results: 138 patients aged 57.02±10.05 years were included in this analysis (69 in each group). At M6 and M12 a significant improvement of the majority of the modifiable risk factors in the Intensive group compared to the Control group was observed. At M12, coronary heart disease (CHD)/fatal-CHD risks were significantly lower in the Intensive (7.5%/3.1%) than in the Control (17.95%/10.3%) group (pConclusions: CHD/fatal-CHD and stroke/fatal-stroke risk burden decreased in newly diagnosed diabetic patients following multi-factorial pharmacotherapy association with intensive lifestyle changes during 1-year follow-up.

  • Open Access

    Fenofibrate improves endothelial function and plasma myeloperoxidase in patients with type 2 diabetes mellitus: an open-label interventional study

    by Cristina Nita, Cornelia Bala, Mihai Porojan, Nicolae Hancu

    Fenofibrate offers a number of benefits on the cardiovascular system and it is plausible that its anti-inflammatory, anti-oxidant and anti-fibrotic effects and enhancement of cardiac metabolic performances may account for its direct cardioprotective effects.


  • Cardio-Metabolic Risk Factors Control in Newly Diagnosed Type 2 Diabetic Subjects

    by Mirela Florea, Cristina Niţă, Răzvan Florea, Nicolae Hâncu

    Background and Aims. The aim of this study was to assess the control of the cardiometabolic risk factors in subjects with newly diagnosed type 2 diabetes (T2DM) one year after initiating the clinical management. Material and Methods. We conducted a prospective observational study including 673 persons with newly diagnosed T2DM, registered at the Clinical Center of Diabetes Cluj-Napoca, between 2006-2008. Results: Of the total T2DM subjects who were followed-up until the end of the first year after diagnosis, the proportion of those reaching the optimal goals for major risk factors was 72.1% for HbA1c, 58.6% for blood pressure (BP) and 40.3% for LDL cholesterol. All three goals were met by only 6.9%. Achieving glycemic targets is associated with a lower HbA1c value at diagnosis (OR:0.66, 95%IC: 0.54-0.81). The parameters which were initially identified as associated with achieving the objectives of the clinical management were represented by age, male gender, clinical parameters (HbA1c, body mass index, BP), hypertension, pharmacotherapy. Conclusions: Implementing clinical management in newly diagnosed T2DM subjects resulted in improved glycemic control and cardiovascular risk factors one year after diagnosis. The management of newly diagnosed people with T2DM focused specifically on achieving the glycemic target


    • 1 January 2004
      • Vol. 42  (2) , 237-45

    Metabolic syndrome--practical approach.

    by Nicolae Hancu, Gabriela Roman, Cristina Nită, Monica Negrean

    The diagnosis of metabolic syndrome is based on identification of the following parameters: abdominal obesity, triglycerides, HDL-cholesterol, blood pressure, fasting glycemia, as recommended by ATP III. In order to simplify the clinical practice, at least two parameters should be screened for. The most frequent couple, easy to be determined in practice, is hypertensive waist, followed by hypertriglyceridemic waist, hypertensive dyslipidemia, dysglycemic dyslipidemia and hypertensive dysglycemia. Based on these couples the next step would be to identify the triads that diagnose the metabolic syndrome. A global assessment of cardiovascular risk should be made. Suggested method is to apply the Framingham Score. Therapeutic intervention is structured according to levels of cardiovascular risk. Clinical management is structured on THEME Programs (therapy, education, monitoring, evaluation), applied to all risk factors.